Two Sigma Advisers LP Buys 357,500 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)

Two Sigma Advisers LP boosted its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 44.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,157,500 shares of the company's stock after acquiring an additional 357,500 shares during the period. Two Sigma Advisers LP owned 0.51% of Gossamer Bio worth $1,047,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Graham Capital Management L.P. bought a new position in shares of Gossamer Bio in the fourth quarter worth about $32,000. Fullcircle Wealth LLC acquired a new position in Gossamer Bio during the 4th quarter valued at about $43,000. Bank of America Corp DE lifted its holdings in shares of Gossamer Bio by 107.2% during the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company's stock worth $77,000 after purchasing an additional 43,866 shares during the period. Jefferies Financial Group Inc. purchased a new stake in shares of Gossamer Bio during the 4th quarter worth about $90,000. Finally, Lazard Asset Management LLC raised its position in shares of Gossamer Bio by 7,992.6% during the 4th quarter. Lazard Asset Management LLC now owns 107,470 shares of the company's stock worth $97,000 after purchasing an additional 106,142 shares during the last quarter. Hedge funds and other institutional investors own 81.23% of the company's stock.

Gossamer Bio Stock Performance

GOSS stock traded up $0.04 during midday trading on Wednesday, hitting $1.26. The stock had a trading volume of 1,430,068 shares, compared to its average volume of 1,554,293. Gossamer Bio, Inc. has a 52 week low of $0.50 and a 52 week high of $1.55. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The stock has a 50-day simple moving average of $1.01 and a 200 day simple moving average of $1.02. The firm has a market capitalization of $286.40 million, a price-to-earnings ratio of -3.94 and a beta of 1.85.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company had revenue of $9.89 million during the quarter, compared to the consensus estimate of $3.95 million. As a group, equities research analysts anticipate that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

Wall Street Analyst Weigh In

GOSS has been the subject of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Gossamer Bio in a research report on Tuesday, March 18th. Wedbush reissued an "outperform" rating and set a $4.00 price target on shares of Gossamer Bio in a research note on Friday, May 16th. Finally, The Goldman Sachs Group lifted their price objective on Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Friday, May 16th.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.